With a study entitled “The microbiome revolution”, Kepler Cheuvreux is today initiating coverage of MaaT Pharma with a purchase recommendation. This new coverage reinforces the visibility of the MaaT Pharma share with institutional, French and international investors and adds to those already carried out by the brokerage firms KBC Securities, Kempen and Portzamparc/BNP Paribas Group.
To receive all of MaaT Pharma’s financial information in real time and for any questions, you can contact us via the following address: [email protected]